Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | EBP | Q15125 | 1/20 | 0.55 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564250 | 1.00 | SIGMAR1 (0.55) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL12156723 | 0.87 | SIGMAR1 (0.44) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL1469872 | 0.86 | SIGMAR1 (0.62) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL1469874 | 0.86 | SIGMAR1 (0.62) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL4021413 | 0.85 | SIGMAR1 (0.66) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL9449900 | 0.83 | SIGMAR1 (0.69) | SIGMAR1EBPKDM4EHTTPOLB | |
| SCHEMBL11131491 | 0.83 | SIGMAR1 (0.69) | SIGMAR1EBPKDM4EHTTPOLB | |
| SCHEMBL14067375 | 0.80 | SIGMAR1 (0.48) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL10129057 | 0.78 | SIGMAR1 (0.69) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL10129761 | 0.78 | SIGMAR1 (0.69) | SIGMAR1EBPPDK1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | claimed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | claimed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | claimed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| EP-1112296-A1 | HIGH GREEN STRENGTH REACTIVE HOT MELT BY A PREPOLYMERIZATION IN THE MAIN REACTOR | National Starch and Chemical Investment Holding Corporation (US) | 2001-07-04 | — | — | EP | claimed |
| WO-2000075209-A1 | HIGH GREEN STRENGTH REACTIVE HOT MELT BY A PREPOLYMERIZATION IN THE MAIN REACTOR | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 2000-12-14 | — | — | WO | claimed |
| EP-0668302-B1 | Catalyst for reactive hot melt adhesives | NAT STARCH CHEM INVEST (US) | 1999-12-22 | — | — | EP | claimed |
| US-4095022-A | PHOSPHORUS COMPOUNDS, SILICA-ALUMINA CATALYST | TEXACO DEVELOPMENT CORPORATION (US) | 1978-06-13 | — | — | US | claimed |
| US-4026935-A | FROM N-(HYDROXYALKYL)-MORPHOLINE COMPOUND, SILICA-ALUMINA CATALYST | TEXACO DEVELOPMENT CORPORATION (US) | 1977-05-31 | — | — | US | claimed |
| JP-6146028-A | — | — | None | — | — | JP | disclosed |
| US-10208169-B2 | Methods of modifying agricultural co-products | BATTELLE MEMORIAL INSTITUTE (US) | 2019-02-19 | — | — | US | disclosed |
| US-9745437-B2 | Method for the preparation of microcellular polyurethane elastomers | SKC CO. LTD. (KR) | 2017-08-29 | — | — | US | disclosed |
| EP-2797975-B1 | METHOD FOR THE PREPARATION OF MICROCELLULAR POLYURETHANE ELASTOMERS | SKC CO LTD (KR) | 2017-06-28 | — | — | EP | disclosed |
| US-20160319083-A1 | Methods of Modifying Agricultural Co-Products and Products Made Therefrom | BATTELLE MEMORIAL INSTITUTE (US) | 2016-11-03 | — | — | US | disclosed |
| EP-0529973-A1 | Fungicidal 2-aryl-2-cyano-2-(heterocyclylalkyl)ethyl-1,2,4-triazoles | ROHM AND HAAS COMPANY (US) | 1993-03-03 | — | — | EP | disclosed |
| EP-0426491-A2 | Herbicidal, optically active or racemic substituted propionic acid derivatives, herbicide compositions containing them and process for preparing same | ALKALOIDA VEGYESZETI GYAR (HU) | 1991-05-08 | — | — | EP | disclosed |
| US-4455168-A | CONTAINING A HETEROCYCLIC, HYDROXY AMINE OR AMIDE | RICOH COMPANY, LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
| US-4095022-A | PHOSPHORUS COMPOUNDS, SILICA-ALUMINA CATALYST | TEXACO DEVELOPMENT CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
| US-4026935-A | FROM N-(HYDROXYALKYL)-MORPHOLINE COMPOUND, SILICA-ALUMINA CATALYST | TEXACO DEVELOPMENT CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | SIGMAR1 360/4885EBP 3668/4885PDK1 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.